DBV Technologies S.A. (DBVT)

NASDAQ: DBVT · IEX Real-Time Price · USD
2.35
-0.20 (-7.84%)
Jul 1, 2022 12:02 PM EDT - Market open

Company Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.

Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.

The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis.

Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes.

The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.

DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBV Technologies S.A.
DBV Technologies Logo
Country France
Founded 2002
Industry Biotechnology
Sector Health Care
Employees 88
CEO Daniel Tasse

Contact Details

Address:
177-181 avenue Pierre Brossolette
Montrouge, Ile De France 92120
France
Phone 33 1 55 42 78 78
Website dbv-technologies.com

Stock Details

Ticker Symbol DBVT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
CIK Code 0001613780
CUSIP Number 23306J101
ISIN Number US23306J1016
SIC Code 2836

Key Executives

Name Position
Daniel Tassé Chief Executive Officer and Director
Sébastien Robitaille Chief Financial Officer
Dr. Pharis Mohideen Chief Medical Officer
Pascal Wotling Chief Technical Operations Officer and Chief Quality Officer
Anne Pollak Head of Investor Relations
Michele F. Robertson Chief Legal Officer
Joseph Becker Vice President of Global Corporate Communications
Caroline Daniere Chief Human Resources Officer and Chief of Staff
Dr. Wence Agbotounou Chief Clinical Trial Officer and Senior Vice President
Lucie Mondoulet Senior Vice President and Deputy CSO

Latest SEC Filings

Date Type Title
Jun 16, 2022 SC 13D/A General statement of acquisition of beneficial ownership
Jun 13, 2022 4 Statement of changes in beneficial ownership of securities
Jun 13, 2022 SC 13D/A General statement of acquisition of beneficial ownership
Jun 13, 2022 8-K Current report
Jun 7, 2022 8-K Current report
May 25, 2022 F-6EF Registration of American Depository Receipt shares, immediately effective
May 16, 2022 8-K Current report
May 2, 2022 8-K Current report
May 2, 2022 424B5 Prospectus [Rule 424(b)(5)]
May 2, 2022 10-Q Quarterly report [Sections 13 or 15(d)]